Thiago Moreno L Souza, Vagner D Pinho, Cristina F Setim, Carolina Q Sacramento, Rodrigo Marcon, Natalia Fintelman-Rodrigues, Otavio A Chaves, Melina Heller, Jairo R Temerozo, André C Ferreira, Mayara Mattos, Patrícia B Momo, Suelen S G Dias, João S M Gesto, Filipe Pereira-Dutra, João P B Viola, Celso Martins Queiroz-Junior, Lays Cordeiro Guimarães, Ian Meira Chaves, Pedro Pires Goulart Guimarães, Vivian Vasconcelos Costa, Mauro Martins Teixeira, Dumith Chequer Bou-Habib, Patrícia T Bozza, Anderson R Aguillón, Jarbas Siqueira-Junior, Sergio Macedo-Junior, Edineia L Andrade, Guilherme P Fadanni, Sara E L Tolouei, Francine B Potrich, Adara A Santos, Naiani F Marques, João B Calixto, Jaime A Rabi
Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels...
January 13, 2023: Nature Communications